Our Pipeline
The Calibr-Skaggs Institute for Innovative Medicines pursues novel approaches to do more than treat—they hold the potential to cure. Our diverse portfolio reflects our vision to tackle tough health challenges through bold initiatives.
Development Status
- Discovery
- Candidate Selection
- IND-Enabling
- Phase 1
- Phase 2
Cancer
CLBR001 + SWI019 (sCAR-T)
B-cell Lymphomas
Phase 1
A novel, switchable chimeric antigen T cell immunotherapy (sCAR-T) with a biologic ‘switch’ that targets CD19, in a phase 1 study (NCT04450069) evaluating safety in patients with relapsed and refractory B-cell malignancies.
Modality
Cell therapy, Biologic
Grant/Partner
AbbVie
Status
Partnered
sCAR-T for Solid Tumors
Phase 1
A novel, switchable chimeric antigen T cell immunotherapy (sCAR-T) incorporating a ‘switch’ that targets solid tumors.
Modality
Cell therapy, Biologic
Grant/Partner
AbbVie
Status
Partnered
CMR215
Immuno-oncology
IND-Enabling
Intravesical small-molecule STING agonist to treat non-muscle invasive bladder cancer.
Modality
Small molecule
Status
Wholly owned
Hematopoietic Differentiation
Myelodysplastic Syndrome
Candidate Selection
Small molecule that overcomes the differentiation blockade in blood cells to treat myelodysplastic syndrome (MDS) and prevent its progression.
Modality
Small molecule
Status
Wholly owned
YAP Inhibitor
Multiple
Candidate Selection
Small-molecule yes-associated protein (YAP) inhibitors that block cancer cell proliferation, overcoming resistance of standard lung cancer combination treatments.
Modality
Small molecule
Status
Wholly owned
Tri-specific Antibody Platform
Multiple
Discovery
Next-generation trispecific antibody that is designed to improve potency and improve tolerability for solid tumors, including breast and lung cancer.
Modality
Biologic
Grant/Partner
Multiple
Status
Wholly owned
CDK2 Inhibitor
Breast Cancer
Discovery
An oral CDK2 inhibitor to treat individuals with ER+, HER2- advanced or metastatic breast cancer who were unresponsive to other therapies.
Modality
Small molecule
Status
Wholly owned
Novel Treatments
Oncology
Discovery
Multiple early-stage small-molecule and biologic programs to treat multiple tumor types, including breast cancer.
Modality
Small molecule, Biologic
Status
Wholly owned
Antibody-Drug Conjugates
Multiple
Discovery
Multiple antibody-drug conjugates (ADCs) that target various cancers, including ovarian, non-small cell lung and small cell lung.
Modality
Small molecule, Biologic
Status
Wholly owned
Drug Synergy
Multiple
Discovery
Repurposed small-molecule drugs that synergize with standard of care chemotherapies using synergy screening of our ReFRAME drug repurposing library.
Modality
Small molecule
Status
Wholly owned
Regenerative Medicine and Diseases of Aging
CLF065
Inflammatory Bowel Disease
Phase 1
A long-acting (fatty acid-stapled) glucagon-like peptide 2 (GLP-2) biologic developed to regenerate the intestinal barrier in inflammatory bowel disease (IBD) with infrequent dosing.
Modality
Biologic
Grant/Partner
AbbVie
Status
Partnered
KA34
Osteoarthritis
Phase 1
A first-in-class small-molecule stimulator of cartilage regeneration deemed safe and well-tolerated in a phase 1 trial.
Modality
Small molecule
Grant/Partner
CIRM
Status
Wholly owned
CMR316
Idiopathic Pulmonary Fibrosis
Phase 1
A first-in-class, small molecule that stimulates in situ lung stem cell self-renewal and tissue regeneration to treat several lung diseases—idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), acute lung injury (ARDS)—with a phase 1 trial in healthy volunteers and patients with IPF in early 2024.
Modality
Small molecule
Status
Wholly owned
Heart Regeneration
Congestive Heart Failure
Candidate Selection
A first-in-class, pericardially injected, small molecule that promotes in situ proliferation of terminally differentiated cardiomyocytes to repair injured heart tissue after myocardial infarction.
Modality
Small molecule
Status
Wholly owned
Corneal Regeneration
Persistent Corneal Epithelial Defects
Discovery
First in class small molecule that promotes corneal epithelial cell regeneration to heal persistent corneal epithelial defects.
Modality
Small molecule
Status
Wholly owned
Novel Therapy
Age-Related Macular Degeneration
Discovery
Small-molecule compounds that stimulate in situ retinal pigment epithelium regeneration to treat age-related macular degeneration (AMD).
Modality
Small molecule
Status
Wholly owned
Neurological Diseases
PDM608
Parkinson’s Disease, Alzheimer's Disease, ALS
Phase 1
A novel long-acting (antibody fusion) GM-CSF protein designed for less frequent dosing in the treatment of neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease.
Modality
Biologic
Grant/Partner
Multiple
Status
Wholly owned
Next Generation Kappa Opioid Receptor Antagonists
Chronic Psychotic Diseases
Candidate Selection
Small-molecule kappa opioid receptor (KOR) antagonists—using our long-acting injectable and oral peptide platforms—to treat various neurological conditions.
Modality
Small molecule
Status
Wholly owned
Novel Treatment
Degenerative Brain Diseases
Discovery
A brain-penetrating, small-molecule that improves BDNF transport to treat neurodegenerative diseases, such as Huntington’s disease.
Modality
Small molecule
Status
Wholly owned
Other Novel Treatments
Neurological Diseases
Discovery
Multiple brain-penetrating biologics and small molecules to address unmet needs in treating neurological diseases.
Modality
Small molecule, Biologic
Status
Wholly owned
Global Health
Mpro Inhibitor
COVID-19
Phase 1
A small molecule SARS-COV-2 Mpro inhibitor was advanced to phase 1 trial, and next-generation molecules are in development.
Modality
Small molecule
Status
Wholly owned
CLZ629
HIV
Phase 1
A long-acting antiretroviral prodrug for HIV using our long-acting injectable platform to reduce dosing frequency, in development as a combination therapy.
Modality
Long-acting injection
Status
Partnered
CBE161 (MMV371)
Malaria
Phase 1
A small-molecule, once-every-2-month intramuscular injectable to prevent seasonal malaria by improving compliance.
Modality
Long-acting injection
Grant/Partner
Medicines for Malaria Venture
Status
Partnered
CLB073 (TBD11)
Tuberculosis
Phase 1
A novel, small molecule derived from a ReFRAME synergy screen that enhances the pretomanid + bedaquiline treatment for tuberculosis.
Modality
Small molecule
Grant/Partner
Bill & Melinda Gates Medical Research Institute
Status
Partnered
CMQ069
Malaria
IND-Enabling
A long-acting small-molecule that uses our long-acting, oral peptide platform to generate a single-dose treatment for malaria.
Modality
Small molecule
Grant/Partner
The John C. Martin Foundation
Status
Wholly owned
Novel Antibacterial
Tuberculosis
Candidate Selection
mCMX410 is a tuberculosis therapy that targets a critical enzyme in cell wall biosynthesis.
Modality
Small molecule
Grant/Partner
Gates Foundation
Status
Wholly owned
Novel Antivirals
COVID-19
Candidate Selection
Multiple novel small-molecule antivirals that inhibit proteins needed for SARS-CoV-2 infection and transmission that will be more durable against resistance and active against future coronavirus strains.
Modality
Small molecule
Grant/Partner
NIH
Status
Wholly owned
Novel Treatments
Cryptosporidiosis
Candidate Selection
Novel small-molecules effective against cryptosporidiosis being optimized as multiple promising leads.
Modality
Small molecule
Grant/Partner
Wellcome Trust
Status
Wholly owned
Vaccine Adjuvants
Multiple
Candidate Selection
An array of novel innate immune-activating small-molecule adjuvants to enhance the efficacy of vaccines for multiple illnesses, including HIV, influenza and COVID.
Modality
Small molecule
Grant/Partner
Gates Foundation
Status
Wholly owned
Novel Treatments
Neglected Tropical Disease
Discovery
Multiple small molecules that treat neglected tropical diseases including Chagas, leishmaniasis, schistosomiasis, dengue virus and others.
Modality
Small molecule
Grant/Partner
Wellcome Trust
Status
Wholly owned
Novel Therapy
Dengue Virus
Discovery
A small molecule identified in a ReFRAME screen to treat dengue.
Modality
Small molecule
Status
Wholly owned
Novel Treatment
Hepatitis C Virus
Discovery
Small-molecules developed with our long-acting platform as more manageable treatments for hepatitis C virus (HCV).
Modality
Small molecule
Status
Wholly owned
Inflammatory and Metabolic Disease
CLBR001 + SWI019 (sCART)
Autoimmune Diseases
Phase 1
Autoimmune application of our novel, switchable chimeric antigen T cell immunotherapy (sCAR-T) with biologic ‘switch’ that targets CD19 on B cells (completed phase 1 for cancer).
Modality
Cell therapy, Biologic
Grant/Partner
AbbVie
Status
Partnered
CBK323
ARDS and COPD
IND-Enabling
A small molecule that targets inflammation to reduce tissue damage and degeneration in chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS).
Modality
Small molecule
Grant/Partner
ArkBio
Status
Partnered
CMZ371
Obesity
IND-Enabling
A next-generation oral bispecific incretin mimic that combines a GLP1R agonist with a GIPR agonist to treat obesity, diabetes and liver disease.
Modality
Biologic
Status
Wholly owned
Novel Anti-fibrotic
Idiopathic Pulmonary Fibrosis, Scleroderma, Radiation Fibrosis
Candidate Selection
A small-molecule compound that targets a fibrotic pathway to alleviate fibrosis in several tissue types, including lung, liver and skin.
Modality
Small molecule
Status
Wholly owned
Novel Anti-Inflammatory
Inflammatory Bowel Disease
Candidate Selection
A small-molecule gut-restricted NRF2 activator that protects the gut lining from inflammation caused by inflammatory bowel disease (IBD) to alleviate IBD symptoms.
Modality
Small molecule
Status
Wholly owned
Novel Treatment
Metabolic dysfunction-associated steatohepatitis (MASH)
Discovery
A novel dual-acting biologic that acts on multiple receptors for the treatment of metabolic dysfunction-associated steatohepatitis.
Modality
Biologic
Status
Wholly owned
Novel Treatment
Obesity
Discovery
Biologic dual and triple agonists using our oral peptide and long-acting injectable platforms for obesity.
Modality
Biologic
Status
Wholly owned